News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TransTech Pharma, Inc. Release: Novel, Oral Drug TTP488 Shows Promise for Disease Modification in Alzheimer’s Patients



10/29/2012 2:38:56 PM

HIGH POINT, N.C.--(BUSINESS WIRE)--A novel, orally administered drug candidate, TTP488, has demonstrated clinical evidence of slowing of cognitive decline over 18 months of therapy in patients with mild to moderate Alzheimer’s disease. TTP488 is a small-molecule drug that is the first to show clinical benefit from research on the receptor for advanced glycation endproducts (RAGE), a new biochemical target in Alzheimer’s disease treatment. TransTech Pharma, Inc. of High Point, North Carolina discovered, developed and owns all rights to this drug candidate.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES